InflaRx N.V. (NASDAQ:IFRX) Stock Has Consensus Target Price of $7.43 According to Analysts

Key Points

• Analysts give InflaRx a “Moderate Buy” consensus: five of nine covering brokerages rate it Buy, one Strong Buy, two Hold, and one Sell. Their average 12-month price target is $7.43.
• Recent analyst moves were mixed: Cantor Fitzgerald raised its target to $6 and kept an Overweight rating, while Needham initiated coverage with a Buy and an $8 target; Zacks Research downgraded the stock to Hold.
• InflaRx reported a quarterly loss of $0.02 per share, beating the $0.06 loss analysts expected. The shares opened at $1.30, and institutional investors own 42.39% of the company.

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received an average rating of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $7.43.

Several equities analysts have recently issued reports on the company. Zacks Research lowered InflaRx from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 25th. Cantor Fitzgerald increased their price objective on shares of InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Needham & Company LLC started coverage on shares of InflaRx in a report on Monday, September 14th. They issued a "buy" rating and a $8.00 price objective for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of InflaRx in a research note on Monday, September 21st.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IFRX. Sanctuary Advisors LLC acquired a new stake in shares of InflaRx in the second quarter valued at about $25,000. AXQ Capital LP bought a new stake in shares of InflaRx during the second quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. boosted its holdings in InflaRx by 47.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 23,600 shares of the company's stock valued at $44,000 after purchasing an additional 7,600 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in InflaRx in the first quarter valued at $142,000. Finally, DCF Advisers LLC acquired a new position in InflaRx during the second quarter worth approximately $512,000. Institutional investors own 42.39% of the company's stock.

InflaRx Stock Down 3.7%

NASDAQ IFRX opened at $1.30 on Friday. The company has a 50-day moving average price of $1.79 and a 200-day moving average price of $1.64. The firm has a market capitalization of $192.32 million, a P/E ratio of -3.35 and a beta of 2.38. InflaRx has a 52 week low of $0.80 and a 52 week high of $2.95.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. As a group, equities research analysts anticipate that InflaRx will post -0.23 EPS for the current year.

InflaRx Company Profile

InflaRx N.V. NASDAQ: IFRX is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company's research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company's lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.